Compare Amgen, Inc. (AMGN) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Microchip Technology Inc. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Microchip Technology Inc. trades at $87 (market cap $48.11B). The key difference: Amgen, Inc. is far larger — about 4.1× Microchip Technology Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MCHP | |
|---|---|---|
Market Cap | $196.12B | $48.11B |
Sector | Health | Technology |
52-Week High | $388.16 | $102.97 |
52-Week Low | $271.18 | $49.02 |
Enterprise Value | $241.41B | $53.40B |
Dividend Yield | 2.77% | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Microchip Technology (MCHP) trades at $88.59, up 0.37% with a bearish technical signal despite recent earnings beats. The stock shows elevated valuation ratios (P/E 402.68, P/S 10.25) amid weak 2025 profitability (net income margin -0.02%), though 2026 forecasts suggest recovery. Recent news highlights AI-driven semiconductor demand and new product launches in aerospace/defense. Cash flow improved to $452M in 2025, but debt remains high at $5.63B.
Outlook: Analyst consensus is strongly bullish (68% buy ratings) with a $115.45 price target, citing AI momentum and cyclical recovery. Risks include high debt, volatile earnings, and sensitivity to semiconductor cycles. The stock offers growth exposure to data center and auto markets but requires monitoring of margin improvement and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
